First-line therapy with rituximab may lower mortality risk in RA patients with lung conditions

(American College of Rheumatology) Patients with rheumatoid arthritis who also have lung involvement often have increased mortality, but first-line therapy with rituximab may help them live longer when compared with the use of TNF inhibitors , according to new research findings presented this week at the 2016 ACR/ARHP Annual Meeting in Washington.